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Effects of suppressing intrarenal angiotensinogen on renal
transforming growth factor-b1 expression in acute ureteral
obstruction.
Background. Angiotensin II (Ang II) mediates the up-
regulation of fibrogenic factors such as transforming growth
factor-b1 (TGF-b1) in chronic renal diseases. In addition, it
has been proposed that the intrarenal renin-angiotensin system
(RAS) is as important as the systemic RAS in kidney disease
progression.
Methods. We suppressed angiotensinogen (AGT) gene ex-
pression in the kidney by transferring recombinant adenoviral
vectors carrying a transgene expressing AGT antisense mRNA,
and determined the effect of the local inhibition of the RAS on
TGF-b1 synthesis in the kidneys of rats with unilateral ureteral
obstruction (UUO). Immediately after UUO, recombinant ade-
novirus vectors were injected intraparenchymally into the cor-
tex of obstructed kidneys.
Results. b-galactosidase (b-gal)–stained kidney sections re-
vealed the efficient transduction of the recombinant adenovi-
ral vectors into tubular epithelial cells. Kidney cortex injected
with AGT antisense showed significantly lower native AGT
mRNA and protein expressions than control UUO kidneys at
24 hours and 5 days post-UUO. TGF-b1 was significantly up-
regulated in the renal cortex 24 hours and 5 days post-UUO,
whereas AGT antisense–injected UUO rats showed signifi-
cantly reduced TGF-b1 expression compared to control UUO
rats. Both fibronectin and collagen type I expressions were in-
creased 24 hours and 5 days post-UUO, and these augmen-
tations were considerably reduced by AGT antisense RNA
treatment.
Conclusion. This study demonstrates that the suppression of
intrarenal RAS prevents the formation of renal cortical TGF-
b1, and of related fibrogenic factors, in early UUO.
Progressive kidney disease is characterized by the ac-
cumulation of fibrotic molecules in the kidney. More-
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over, data indicate that angiotensin II (Ang II) plays a
crucial role in mediating the up-regulation of fibrogenic
factors, like transforming growth factor-b1 (TGF-b1), in
various kidney diseases. Ang II elevates blood pressure
and constricts efferent kidney arterioles, which, in turn,
increases intraglomerular pressure. The resulting strain
on glomeruli is considered to stimulate TGF-b1 produc-
tion. Additionally, it has been suggested that Ang II di-
rectly stimulates the synthesis of TGF-b1, a hypothesis
supported by in vitro studies, in which hemodynamic ef-
fects were absent [1]. It has been reported that all of
the components of the renin-angiotensin system (RAS)
exist in the kidney [2, 3]. Furthermore, it was proposed
that the intrarenal RAS is as important as the systemic
RAS in terms of kidney disease progression, and that the
intrarenal RAS is an independent system, which func-
tions in the absence of communication with the circulat-
ing RAS [4, 5].
Unilateral ureteral obstruction (UUO), a model of ex-
perimental hydronephrosis, is characterized by tubuloin-
terstitial fibrosis in the obstructed kidney. Published data
show that an Ang II increase stimulates TGF-b1 synthe-
sis, thereby causing interstitial fibrosis in the obstructed
kidney. Indeed, blockades of RAS using Ang II recep-
tors [6], angiotensin-converting enzyme (ACE) inhibitors
[7] or angiotensinogen (AGT) knockout [8] have been
shown to prevent increased TGF-b1 expression and even-
tual fibrosis in obstructive nephropathy. However, these
studies, in which systemic RAS was a primary target, do
not provide direct evidence on the function of intrarenal
RAS. The relationship between intrarenal RAS and fi-
brogenic molecules may have significant clinical implica-
tions, given that the systemic inhibition of RAS is often
accompanied by side effects, which prohibit the use of
Ang II inhibitors in patients with chronic renal diseases.
In the present study, we attenuated AGT gene expres-
sion in the kidney by transferring recombinant adenoviral
vectors carrying a transgene expressing AGT antisense
mRNA, and then determined the effect of this local
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Fig. 1. Rat angiotensinogen gene, exon 2 (accession no. L00091). Underlined is cloned sequence; bold type is coding sequence (54. . . 882); lower
case is intron (<1. . . 23), (>883. . . 907).
inhibition of the RAS on TGF-b1 synthesis in UUO rats.
To our knowledge, this is the first study to selectively
target the kidney in vivo to investigate the relationship
between intrarenal RAS and fibrogenic molecules.
METHODS
Animal surgery
Male Wistar rats (Japan SLC, Shizuoka, Japan) weigh-
ing 250 to 300 g were subjected to UUO or to a sham op-
eration. After anesthesia, the left kidney and the ureter
were exposed by a midabdominal incision, and the left
ureter was ligated with 4-0 silk. The sham operation
for control kidneys consisted of a similar midabdom-
inal incision and visualization of the left ureter with-
out further manipulation. Immediately after UUO, re-
combinant adenovirus vectors were injected into three
to four sites at the lower part of the left renal cortex
using 30 gauge needles. UUO rats were divided into
three groups that received either (1) recombinant ade-
noviruses containing the LacZ gene (rAdLacZ), (2) re-
combinant adenoviruses containing an AGT antisense
transgene (rAdAGT/antisense), or (3) no treatment. Ap-
proximately 1 × 1010 plaque-forming units were delivered
in 600 uL phosphate-buffered saline (PBS). Kidneys were
harvested at 24 hours and 5 days post-UUO to evaluate
TGF-b1, fibronectin, and collagen type I synthesis. Se-
rial changes of AGT expression were observed at 6 and
24 hours and 5 days post-UUO. Harvested kidneys were
bisected and samples of cortical tissues were obtained
from the injected areas. Samples were then snap frozen
immediately in liquid nitrogen and kept at −70◦C until
required. All animal experiments were undertaken in ac-
cordance with the guidelines of the Animal Committee
of Ajou University.
Construction of recombinant adenoviruses
Two DNA fragments containing bases −30 to +191
(221 bp) or +601 to +829 (229 bp) of rat AGT exon
2 were isolated from a rat liver cDNA library (Clon-
tech, Palo Alto, CA, USA) (Fig. 1). The 229 bp and 221
bp fragments were ligated in a reverse orientation, into
the NheI-ApaI and xbaI-KpnI restriction sites of a shut-
tle vector (Clontech), respectively, to construct pShuttle-
AGT/antisense, which was subsequently sequenced to
confirm the orientations and the positions of the trans-
genes (data not shown). The AGT/antisense expression
cassette containing the cytomegalovirus (CMV) pro-
moter of pShuttle-AGT/antisense was subcloned into an
adenovirus type 5 backbone, pAdeno-X (Clontech) to
generate pAdenoAGT/antisense. Subsequently, human
embryonic kidney-293 (HEK-293) cells were transfected
with pAdenoAGT/antisense to produce replication de-
fective recombinant adenoviruses, rAdAGT/antisense.
Harvested recombinant adenoviruses were purified us-
ing adenovirus purification filters (Clontech), and then
further concentrated using Centricon YM-50 centrifugal
filter units (Millipore, Billerica, MA, USA). Viral stocks
were titered by infecting HEK-293 cells with serial dilu-
tions of the viral preparation at 37◦C.
RNA isolation
Kidney specimens were homogenized in Trizol reagent
(Life Technologies, Rockville, MD, USA). RNA was ex-
tracted with chloroform, precipitated with isopropanol,
washed with 75% ethanol, and then redissolved in Tris
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Table 1. Primers used in the polymerase chain reactions
Primers Sequences (expected size) Location (Genbank)
GADPH Forward 5′-TGTTCCAGTATGACTCTACCC-3′ 980–1000
Reverse 5′-TCATGAGCCCTTCCACGATG-3′ 1350–1369
(390 bp) (AF 106860)
AGT Forward 5′-GATAAGCTCGTGCTGGCCAC-3′ 229–248
Reverse 5′-ACCACGGTGGACTGTAGCAG-3′ 577–596
(368 bp) (NM 134432)
TGF-b1 Forward 5′-GGATACCAACTACTGCTTCAG-3′ 1252–1272
Reverse 5′-ACGATCATGTTGGACAACTGC-3′ 1543–1563
(312 bp) (NM 021578)
Fibronectin 5′-CACTGGAAACACTTACAAAGTG-3′ 306–327
5′-CAGACACAAACACTCCAACATA-3′ 492–513
(208 bp) (X 15906)
Collagen type I 5′-TGTATGCTTGATCTGTATCTGC-3′ 141–162
5′-AGCAAAGTTTCCTCCAAGACC-3′ 430–450
(310 bp) (Z 78279)
Abbreviations are: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; AGT, angiotensinogen; TGF-b1, transforming growth factor-b1.
Table 2. Composite primers used to construct competitor DNA templates
Primers Sequences (expected size) Location In pShuttle
GAPDH competitor Forward 5′-TGTTCCAGTATGACTCTACCCggcggtgctacagagttctt-3′ (1971–1990)
Reverse 5′-TCATGAGCCCTTCCACGATGttcgttccactgagcgtcag-3′ (2200–2219)
(290 bp)
AGT competitor Forward 5′-GATAAGCTCGTGCTGGCCACggcctaactacggctacact-3′ (1999–2018)
Reverse 5′-ACCACGGTGGACTGTAGCAGttcgttccactgagcgtcag-3′ (2200–2219)
(261 bp)
TGF-b1 competitor Forward 5′-GGATACCAACTACTGCTTCAGggcggtgctacagagttctt-3′ (1971–1990)
Reverse 5′-ACGATCATGTTGGACAACTGCtgcgcgtaatctgctgcttg-3′ (2135–2154)
(226 bp)
Fibronectin competitor 5′-CACTGGAAACACTTACAAAGTGctgaagccagttaccttcgg-3′ (2049–2068)
5′-CAGACACAAACACTCCAACATAtgcgcgtaatctgctgcttg-3′ (2135–2154)
(150 bp)
Collagen type I competitor 5′-TGTATGCTTGATCTGTATCTGCggcggtgctacagagttctt-3′ (1971–1990)
5′-AGCAAAGTTTCCTCCAAGACCtgcgcgtaatctgctgcttg-3′ (2135–2154)
(227 bp)
Abbreviations are: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; AGT, angiotensinogen; TGF-b1, transforming growth factor-b1. The 5′ end sequence
(upper case) is gene-specific (refer to Table 1), and the 3′ end sequence (lower case) is pShuttle-specific.
and ethylenediametetraacetic acid (EDTA) (TE) buffer.
The isolated RNA was quantified spectrophotometri-
cally.
Reverse transcription (RT)
After removing contaminated DNA from the iso-
lated RNA using DNase I (Invitrogen, Carlsbad, CA,
USA), 1 lg of total RNA was reverse transcribed into
cDNA in 20 lL reaction mixtures containing; 200 U
of Moloney murine leukemia virus reverse transcrip-
tase, 100 ng/reaction of random hexanucleotide primers,
and 0.5 mmol/L of each of deoxynucleoside triphos-
phates (dNTPs): deoxyadenosine triphosphate (dATP),
deoxycytidimine triphosphate (dCTP), deoxyguanosine
triphosphate (dGTP), and deoxythymidine triphosphate
(dTTP). The reaction mixtures were then incubated at
37◦C for 1 hour and at 65◦C for 10 minutes to deactivate
the reverse transcriptase.
Competitive polymerase chain reaction (PCR)
Competitive PCR was performed to quantify mRNA
using the competitor constructs of each gene, as described
previously [9–11]. Competitor constructs were designed
to be flanked by sequences recognized by a pair of tar-
get gene–specific primers (Table 1), and to contain an
intervening sequence which differed in size from the
target DNA. Competitor constructs were generated by
PCR amplifications using composite primers (Table 2).
Each composite primer had target gene primer sequences
attached to the 20-22mer oligonucleotide, which was
designed to hybridize to the DNA strands of pShuttle.
After the PCR amplifications, the PCR products were
purified by agarose gel electrophoresis, quantitated by
spectrophotometry, and serially diluted. To quantify the
transcript levels, a standard curve for each molecule was
generated by coamplifying a known amount of target
gene cDNA with serial dilutions of a known amount of
the competitor. A standard curve was prepared by plot-
ting the log values of the competitor/cDNA band inten-
sities ratios (y axis) against the log values of the amounts
of the competitor/cDNA ratios (x axis). The individual
PCRs were performed by coamplifying the target cDNA
with a known amount of the competitor. PCRs were per-
formed over 30 cycles for glyceraldehyde-3-phosphate
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Fig. 2. Gene delivery by intraparenchymal injection. (A1 and A2) Recombinant adenovirus vectors carrying the LacZ gene (rAdlacZ) were injected
into the lower part of the left kidney. After removal at 24 hours post-unilateral ureteral obstruction (UUO), the kidney was halved lengthwise and
one of these halves was immersed in X galactosidase (X-gal) staining solution for 1 hour. Note the significant transduction of rAdlacZ over a diffuse
area of the kidney. (A1) Cut surface. (A2) Subcapsular surface. Both the subcapsular surface and the cut surface of the halved kidney were diffusely
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Fig. 3. The serial changes in angiotensinogen (AGT) expression in the
kidney cortex. AGT expression in the unilateral ureteral obstruction
(UUO) kidney was significantly increased at 6 hours post-UUO (N
= 6), and thereafter returned to the sham-control level (N = 8). ∗P
< 0.05 compared with the sham-control (unpaired t test). GADPH is
glyceraldehyde-3-phosphate dehydrogenase.
dehydrogenase (GAPDH), AGT, and fibronectin, and
over 33 cycles for TGF-b1 and collagen type I using a
Perkin-Elmer 9600 Thermo Cycler (Perkin-Elmer, Shel-
ton, CT, USA). The amplification profile consisted of
denaturing at 94◦C for 20 seconds, primer annealing at
57◦C for 30 seconds, and primer extension 72◦C for 20
seconds in all cases. The PCR products were applied to
2% agarose gels, resolved by electrophoresis, and ana-
lyzed using a Gel Doc 2000 image analyzer (Bio-Rad,
Hercules, CA, USA) to determine the ratios of the ab-
sorbance values of target cDNA to the competitor pairs.
Using the standard curve, the amount of target cDNA was
then calculated from the competitor/cDNA band inten-
sity ratio. Target gene product amounts were normalized
versus those of GAPDH, and the results were expressed
as ficogram of target gene per picogram of GAPDH.
Histochemical staining for b-galactosidase (b-gal) (LacZ)
Kidneys injected with rAdlacZ were harvested for
the histochemical detection of b-gal at 24 hours post-
UUO. Before removal, the left kidney was selectively
perfused with 2% formaldehyde/0.2% glutaraldehyde
via a catheter inserted into the aorta below the left
renal artery. For gross staining, kidney tissue blocks
stained by the X-gal staining solution. This demonstrates that adenovirus infiltrated diffusely from the outermost (subcapsular surface) through to
the innermost region (cut surface) of the kidney. (A3 and A4) The halved and b-gal stained kidney (A1 and A2) was embedded in paraffin and then
sectioned vertically to the cut plane. Sections were counterstained with hematoxylin and eosin. Note the intense b-gal staining within the kidney
tubules. The X-gal staining solution does not penetrate the tissue block, and therefore, it stained only directly contacted tissue [magnification ×100
(A3) and ×400 (A4)]. (B1 to B3) Frozen sections of rAdlacZ injected kidneys. Cryostat sections were incubated in X-gal staining solution for 2
hours at 37◦C and stained for b-gal. (B1) The control kidney with UUO showing negative b-gal activity (magnification ×40). (B2) Note significant
rAdlacZ transduction over a diffuse area in the cortex. The injection site was most intensely stained by b-gal (arrow) (magnification ×40). (B3)
Transduction appeared to be particularly efficient in tubular epithelial cells (magnification ×400).
were stained for 1 hour in 5-bromo-4-chloro-3-indolyl-
b-D-galactopyranoside (X-gal) staining solution (Roche
Diagnostics, Mannheim, Germany). The X-gal–stained
kidney was refixed, paraffin-embedded, and 4 lm sec-
tions were counterstained with hematoxylin and eosin.
For frozen section staining, cryostat sections (6 lm)
were fixed in 2% formaldehyde/0.2% glutaraldehyde for
10 minutes, and then washed with PBS. Fixed sections
were incubated in X-gal staining solution for 2 hours at
37◦C. The sections were then counterstained with hema-
toxylin.
Sandwich enzyme-linked immunosorbent assay (ELISA)
for TGF-b1
Renal tissue segments were homogenized in ly-
sis buffer (pH 7.5) containing 1.0% Triton X-100,
150 mmol/L NaCl, 5 mmol/L EDTA, 50 mmol/L Trizma,
and protease inhibitor cocktail (Roche Diagnostics), and
homogenates were centrifuged at 15,000g at 4◦C for
10 minutes. The tissue extracts obtained were analyzed
for TGF-b1 using commercially available ELISA kits
(R&D Systems, Minneapolis, MN, USA), according to
the manufacturer’s specifications. In order to measure to-
tal TGF-b1, samples were activated by acidification with
1 N HCl to convert latent into active TGF-b1, and then
neutralized by adding 1.2 N NaOH/0.5 mol/L Hepes.
Western blot analysis for fibronectin and AGT
Renal tissue extracts were subjected to 8% (fi-
bronectin) or 12% (AGT) acrylamide gel sodium
dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), and Western blotted. Thirty micrograms
(fibronectin) or 60 lg (AGT) of protein was subjected
to SDS-PAGE and blots were then transferred to a
nitrocellulose membrane. They were then exposed to
antifibronectin antibody (Chemicon, Temecula, CA,
USA), or antirat AGT antibody (Research Diag-
notics, Inc., Flanders, NJ, USA) and incubated with
peroxidase-conjugated antirabbit IgG (Chemicon), or
antimouse IgG (Santa Cruz Biotechnolgy, Santa Cruz,
CA, USA). The reaction was developed with ECL
reagent (Amersham biosciences, Piscataway, NJ, USA).
Histologic examinations
Five days post-UUO tissue sections were stained with
Masson trichrome to examine the degree of interstitial
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Fig. 4. Polymerase chain reaction (PCR)
for angiotensinogen (AGT) antisense (AS)
mRNA at 24 hours and 5 days post-unilateral
ureteral obstruction (UUO). (A) Primers
were designed to detect only AGT antisense
mRNA (refer to text). Only left kidneys (LK)
injected with the recombinant adenovirus car-
rying the AGT antisense gene yielded the
506 bp PCR product. RK is right kidney. (B)
Primers were designed to detect both AGT
antisense mRNA (217 bp) and native AGT
mRNA (612 bp) in one reaction mixture (re-
fer to text). AGT antisense RNA expression
markedly exceeded that of AGT mRNA (ra-
tios 9.3 ± 1.06 at 24 hours and 8.8 ± 0.57 at 5
days post-UUO).
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Fig. 5. Angiotensinogen (AGT) expression in the kidney cortex at 24 hours and 5 days post-unilateral ureteral obstruction (UUO). (A) The kidney
injected with AGT antisense (UUO/antisense) showed significantly lower endogenous AGT mRNA expression than obstructed kidneys injected
with (UUO/LacZ) or without LacZ gene (UUO). ∗P < 0.05 vs. sham, UUO/LacZ, or UUO [by analysis of variance (ANOVA)]. Values are means
± SEM (N = 8). (B) AGT standard curve. y = log (competitor band intensity/cDNA band intensity), x = log (competitor in pg/cDNA in pg). The
cDNA size was 368 bp and the competitor 261 bp (100 bp DNA ladder). GADPH is glyceraldehyde-3-phosphate dehydrogenase.
fibrosis. Under high power magnification (×400), 16 ran-
dom nonoverlapping fields per rat (eight rats per group)
were obtained from the cortical region in the lower half
of the kidney which was the area targeted by the aden-
ovirus injection (Fig. 2A1 and A2), and comparisons were
made between the sham, LacZ, and the antisense-treated
groups. Masson trichrome staining was semiautomati-
cally quantified in 16 fields per slide using MetaMorph im-
age analysis software 6.1 (Universal Imaging Co., Down-
ingtown, PA, USA), and was expressed as a percentage
of the field area [12, 13].
Statistical analysis
All results are expressed as means ± SEM. Statisti-
cal significance between multiple groups was evaluated
by analysis of variance (ANOVA) with the Bonferroni
correction. The unpaired t test was used to compare con-
tinuous variables between two groups. A P value of <0.05
was considered significant.
RESULTS
Transduction of the LacZ gene in the kidney
To determine whether renal cells are transduced by
adenovirus in vivo, we injected rAdlacZ directly into the
renal parenchyma. b-gal–stained sections revealed sig-
nificant rAdlacZ transduction over a diffuse area in the
cortex (Fig. 2). The transfection was particularly efficient
in tubular epithelial cells (Fig. 2).
Serial changes of AGT mRNA expression
in the renal cortex
AGT mRNA expression in the kidney peaked 6 hours
after ureteral obstruction and then returned to the sham
level at 24 hours and 5 days (Fig. 3).
Effects of AGT as on native AGT mRNA and protein
To check AGT antisense RNA expression in vari-
ous organs of the rAdAGT/antisense-injected rats, the
liver, which is the main source of systemic AGT, and
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Fig. 6. Western blot demonstrating that angotensinogen (AGT) an-
tisense (AS) gene significantly suppressed AGT protein expression
in the obstructed kidneys [unilateral ureteral obstruction/antisense
(UUO/AS)]. (A) At 24 hours post-UUO. (B) At 5 days post-UUO.
(C) The results shown are the ratio of the absorbance of the AGT
bands and the corresponding glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) bands. ∗P < 0.05 vs. sham, UUO/LacZ, or UUO [by
analysis of variance (ANOVA)]. Values are means ± SEM (N = 8).
both kidneys were harvested for RT-PCR. Primers were
designed to hybridize to the NheI-ApaI inserted anti-
sense fragment and the immediate downstream sequence
of the multicloning site of the shuttle vector (forward
5′-CTTGGAAGTGAACGTAGGTGTT-3′ and reverse
5′-AGGCTGATCAGCGGTTTAAAC-3′). The 506 bp
PCR product of AGT antisense RNA was detected only
in rAdAGT/antisense-injected kidneys (Fig. 4).
It has been previously shown that the antisense mRNA
level should exceed that of the target gene appreciably
in order to suppress target gene mRNA [14]. To esti-
mate the relative level of AGT antisense mRNA and
native AGT mRNA in the rAdAGT/antisense-injected
cortex, a PCR amplification was performed using a pair
of primers targeting the two cloned antisense sequences.
These primers allowed the differentiation of native AGT
from AGT antisense RNA on the basis of PCR product
size. Native AGT gave a PCR product of 612 bp, com-
pared with a 217 bp product for AGT antisense RNA.
Both PCR products were produced in one reaction mix-
ture using the same primers, hence, the amplification effi-
ciency of both templates was considered equal. As shown
in Figure 4, AGT antisense RNA expression was signif-
icantly higher than AGT mRNA expression at 24 hours
and 5 days post-UUO, and the ratio of AGT antisense
RNA to AGT mRNA was approximately 9 (9.3 ± 1.06 at
24 hours and 8.4 ± 0.44 at 5 days).
Native AGT mRNA expression in the kidney cor-
tex was evaluated by competitive PCR using primers
hybridizing mRNA sequences lying between the two
cloned fragments. Kidney cortices injected with recom-
binant adenoviruses carrying AGT antisense showed
significantly lower AGT mRNA expression than the con-
trol UUO kidneys at 24 hours and at 5 days post-UUO
(Fig. 5). Western blotting demonstrated that AGT anti-
sense treatment significantly suppressed AGT protein ex-
pression in the obstructed kidneys at 24 hours and 5 days
post-UUO (Fig. 6).
Effects of the suppression of AGT mRNA on TGF-b1
mRNA and protein
Initially, we injected PBS into rat kidneys to evalu-
ate the effects of the injection technique itself on the
expression of TGF-b1 mRNA, and found that TGF-b1
was only marginally increased at 24 hours post-UUO
by the PBS injection (data not shown). Renal TGF-b1
mRNA expression 6 hours post-UUO was similar to that
of the sham-operated controls, but was significantly up-
regulated at 24 hours and 5 days post-UUO. However,
kidney cortex injected with the AGT antisense showed
significantly suppressed TGF-b1 mRNA expression at
24 hours and 5 days post-UUO compared to the control
UUO kidneys (Fig. 7). Similarly, The TGF-b1 protein
concentrations (TGF-b1/total protein) (pg/mg) showed
an increase 24 hours and 5 days post-UUO, whereas AGT
antisense-injected kidneys showed a significant decrease
compared to the control UUO kidneys (Fig. 8).
Effects of AGT as transduction on collagen type I and
fibronectin mRNA expressions
As was shown by TGF-b1, both fibronectin and colla-
gen type I mRNA expressions were increased 24 hours
and 5 days post-UUO, and similarly both of these aug-
mentations were considerably attenuated by AGT anti-
sense (Figs. 9 and 10).
Effects of the suppression of AGT mRNA on fibronectin
protein
Western blotting demonstrated that AGT antisense
treatment significantly suppressed fibronectin protein ex-
pression in the obstructed kidneys at 24 hours and 5 days
post-UUO (Fig. 11).
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Fig. 8. Transforming growth factor-b (TGF-b1) protein levels corrected
for total protein concentrations (pg/mg), enzyme-linked immunosor-
bent assay (ELISA). Kidney cortex injected with the angiotensino-
gen (AGT) antisense gene (UUO/AS) showed significant TGF-b1 pro-
tein down-regulation. ∗P < 0.05 vs. obstructed kidneys treated with
(UUO/LacZ) or without the LacZ gene (UUO). [by analysis of vari-
ance (ANOVA)]. Values are means ± SEM (N = 8).
Histologic examinations
Measurements of the areas of fibrosis in Masson
trichrome tissue sections at 5 days post-UUO showed
that in the AGT antisense-treated kidneys, fibrotic areas
were significantly reduced versus the control obstructed
kidneys treated with the LacZ gene (Fig. 12).
DISCUSSION
To inhibit RAS using antisense-based methods, AGT
is the target of choice because it is the only known pre-
cursor molecule of the active peptide Ang II. Indeed,
studies have shown that the inhibition of AGT synthesis
reduces Ang II concentrations [5, 15, 16]. In the present
study, AGT antisense RNA was found to reduce AGT ex-
pression in the kidney, and this down-regulated TGF-b1
production and related fibrogenic factors, fibronectin and
collagen type I. These results provide the first in vivo ev-
idence, to our knowledge, that the selective suppression
of intrarenal RAS can block the up-regulation of TGF-
b1 expression in the kidney. Few in vivo studies involving
the selective manipulation of the intrarenal environment
have been undertaken because of a lack of tools capable
of selectively targeting the kidney. Recently, significant
advances made in the area of gene transfer have shown
that an adenoviral system is one of the most powerful
means of delivering genetic material into a wide spec-
trum of cells, including renal cells of mesangial and tubu-
lar origin [17]. In animals, however, gene transfer into
the kidney remains a challenge, although several stud-
ies have described the in vivo adenoviral transfection of
renal tissue using intraarterial [18, 19], retrograde [20],
or intraparenchymal injection [21] techniques. Of these
techniques, we chose to use the intraparenchymal route
because it invariably produced high reporter gene ex-
pressions in the kidney as shown by Choi et al [21] during
our preliminary experiments (data not shown). As evi-
denced by LacZ gene staining (Fig. 2), the transgene was
well expressed in renal tissue, particularly in cortical tubu-
lar cells. Given the fact that the proximal tubules occupy
approximately two thirds of the volume of the kidney cor-
tex and account for 80% of cortical epithelial cells [22],
the majority of cells transfected with adenovirus in this
study may well have been proximal tubular cells. More-
over, proximal tubules are known to be the main source
of AGT and the main contributors to increased TGF-b1
mRNA expression in obstructed kidneys [23]. Hence, it
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Fig. 9. Fibronectin mRNA abundances by competitive polymerase chain reaction (PCR) were expressed as fibronectin (fg)/glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (pg) ratios. (A) Unilateral ureteral obstruction (UUO) rats injected with angiotensinogen (AGT) antisense
showed significantly down-regulated fibronectin levels. ∗P < 0.05 vs. obstructed kidneys treated with (UUO/LacZ) or without the LacZ gene (UUO)
[by analysis of variance (ANOVA)]. Values are means ± SEM (N = 8). (B) Fibronectin standard curve. y = log (competitor band intensity/cDNA
band intensity), x = log (competitor in pg/cDNA in pg). The cDNA size was 208 bp and the competitor 150 bp (100 bp DNA ladder).
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Fig. 10. Collagen type I mRNA abundances by competitive polymerase chain reaction (PCR) were expressed as type I collagen (fg)/glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) (pg) ratios. (A) Unilateral ureteral obstruction (UUO) rats injected with angiotensinogin (AGT) antisense
(AS) showed a significant down-regulation of collagen type I. ∗P < 0.05 versus obstructed kidneys treated with (UUO/LacZ) or without the LacZ
gene (UUO) [by analysis of variance (ANOVA)]. Values are means ± SEM (N = 8). (B) Collagen type I standard curve. y = log (competitor band
intensity/cDNA band intensity), x = log (competitor in pg/cDNA in pg). The cDNA size was 310 bp and the competitor 227 bp. (100 bp DNA
ladder).
is likely that the down-regulation of TGF-b1 observed in
the current study is a consequence of the suppression of
Ang II production in proximal tubular cells.
Regarding the relationship between AGT and fibro-
genic factors, convincing data indicate that AGT accounts
for a substantial portion of fibrotic molecule production
and subsequent renal fibrosis in obstructive nephropa-
thy. Ricardo et al [24] showed that the blockade of AGT
mRNA with antisense oligonucleotides significantly in-
hibits the up-regulation of osteopontin levels in cultured
proximal tubular cells subjected to cyclic mechanical
stretching, which was used to mimic increased tubular
luminal pressure resulting from the ureteral obstruction.
Fern et al [8] used a mouse model of UUO, which was
constructed to have one, two, three, or four copies of the
AGT gene, and demonstrated that AGT expression is
responsible for at least 50% of TGF-b1 synthesis and
subsequent renal fibrosis.
In the present study, we aimed to suppress intrarenal
AGT expression to reduce intrarenal Ang II production
to prevent the up-regulation of TGF-b1 while leaving
systemic Ang II unaffected. Evidence continues to accu-
mulate to support the idea that the local RAS rather than
the systemic RAS is responsible for a large part of Ang
II–dependent effects in the kidney. Since plasma AGT
has a very high molecular weight, only a small fraction
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Fig. 11. Western blot demonstrating that angotensinogen (AGT) an-
tisense (AS) gene significantly suppressed fibronectin protein expres-
sion in the obstructed kidneys [unilateral ureteral obstruction/antisense
(UUO/AS)]. (A) At 24 hours post-UUO. (B) At 5 days post-UUO. (C)
The results shown are the ratio of the absorbance of the fibronectin
bands and the corresponding glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) bands. ∗P < 0.05 vs. obstructed kidneys treated with
(UUO/LacZ) or without LacZ gene (UUO) [by analysis of variance
(ANOVA)]. Values are means ± SEM (N = 8).
of it could be expected to filter across the glomerular
membrane, and, in fact, it has been reported that plasma
contributes less than 5% to 10% to proximal tubular
AGT (reviewed in [25]). Accordingly, Braam et al [26]
blocked and microperfused proximal tubular segments
and collected fluid samples from a downstream segment,
and they found that the proximal tubules secrete sub-
stantial amounts of Ang II or a precursor of Ang II into
the tubular lumen. Reports by others, in which the prox-
imal tubule fluid concentrations of Ang II were found to
be markedly higher than plasma concentrations, suggest
that substantial amounts of Ang II are released into or
generated within intrarenal fluid compartments [27, 28].
Therefore, much of the intrarenal Ang II may be the con-
sequence of intrarenal synthesis, and locally synthesized
Ang II may act in an autocrine and/or a paracrine manner
to stimulate TGF-b1 expression in the kidney.
In the present study, the significant elevation of AGT
expression observed in the obstructed kidney at 6 hours
post-UUO was not sustained at 1 or 5 days post-UUO.
Similar findings have been reported by others, although
few reports have been published concerning renal AGT
in the obstructed kidney. Ricardo et al [24] demonstrated
that UUO results in increased AGT mRNA expression
in the proximal tubules of obstructed kidneys at 6 hours
post-UUO, and el-Dahr et al [29] showed that renal AGT
mRNA is suppressed in the obstructed kidney at 1 and
5 weeks post-UUO. In addition, they showed that sys-
temic (hepatic) AGT mRNA levels are either suppressed
or normal at 1 and at 5 weeks post-UUO [29]. On the
other hand, it appears that Ang II generation in the kid-
ney is increased for an extended period post-UUO. Pi-
mentel et al [30] and el-Dahr et al [29] demonstrated that
renal Ang II concentrations are increased within hours
post-UUO, and that they remain elevated at 1 and 5 weeks
post-UUO in the obstructed kidney. Taken together, re-
nal Ang II levels may be persistently elevated for an ex-
tended period in obstructive nephropathy, whereas renal
AGT levels may be elevated only during the early period
after ureteral obstruction. Regarding the effect of sup-
pressing AGT on Ang II production in such UUO mod-
els, Fern et al [8] showed that the systemic suppression of
AGT reduces kidney fibrosis in UUO mice, which should
be a consequence of the suppression of systemic and/or
renal Ang II production. Similarly, in hypertensive rats
where Ang II levels are elevated despite normal levels of
AGT, AGT was again a successful target for suppressing
Ang II levels in plasma [31]. In the present study, despite
the transient increment of AGT, it is likely that Ang II lev-
els in the kidney cortex remained persistently elevated in
the obstructed kidneys, and that the suppression of AGT
by AGT antisense led to a down-regulation of Ang II and
a subsequent down-regulation of TGF-b1 expression. A
determination of Ang II contents may confirm this sug-
gestion, although currently available techniques need to
be improved to allow the accurate assessment of Ang II
contents in the kidney cortex, since the time required for
even a simple separation of cortex from medulla may sig-
nificantly alter the measured Ang II levels [32].
CONCLUSION
The present study demonstrates that the suppression of
the intrarenal RAS by AGT antisense RNA prevents the
formation of renal cortical TGF-b1, and of related fibro-
genic factors during the early period of renal injury. This
result suggests that the local RAS functions in the kidney
independently of the classical blood-borne system. Ad-
ditionally, our data show that an intraparenchymal injec-
tion of adenoviral vectors enables the efficient transfer of
transgene into tubular epithelial cells of the kidney. More-
over, our observation that AGT antisense suppresses the
synthesis of fibrogenic molecules may lead to a potential
therapeutic intervention for progressive kidney diseases.
Therapy targeting the kidney RAS may have significant
clinical implications in view of the side effects derived
from blocking the systemic RAS.
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Fig. 12. Masson trichrome staining of kidney sections at 5 days post-unilateral ureteral obstruction (UUO) (magnification ×400). The blue stained
fibrotic area was significantly reduced in angiotensinogen (AGT) antisense RNA-injected kidneys (UUO/AS) compared to that seen in obstructed
kidneys treated by LacZ gene injection (UUO/LacZ). Masson trichrome staining was expressed as a percentage of the field area. ♣P < 0.01 vs.
UUO/LacZ (by Student t test) (magnification, ×400). Values are means ± SEM (16 fields per rat, eight rats per group).
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